Eyenovia (NASDAQ:EYEN) Releases Quarterly Earnings Results, Meets Expectations

Eyenovia (NASDAQ:EYENGet Free Report) posted its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17), Yahoo Finance reports. During the same quarter in the previous year, the business posted ($0.17) EPS.

Eyenovia Price Performance

Eyenovia stock opened at $1.18 on Wednesday. Eyenovia has a 12-month low of $1.05 and a 12-month high of $5.85. The company has a current ratio of 4.05, a quick ratio of 4.04 and a debt-to-equity ratio of 0.70. The firm has a 50 day simple moving average of $1.76 and a 200-day simple moving average of $1.64.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a research report on Tuesday.

Check Out Our Latest Analysis on Eyenovia

Institutional Investors Weigh In On Eyenovia

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Two Sigma Securities LLC purchased a new position in Eyenovia in the 2nd quarter worth about $27,000. Goldman Sachs Group Inc. purchased a new position in shares of Eyenovia in the second quarter worth approximately $28,000. Virtu Financial LLC acquired a new stake in shares of Eyenovia during the fourth quarter valued at approximately $26,000. Prudential Financial Inc. purchased a new stake in shares of Eyenovia in the 2nd quarter valued at approximately $33,000. Finally, Wells Fargo & Company MN boosted its stake in Eyenovia by 160.1% in the 2nd quarter. Wells Fargo & Company MN now owns 18,564 shares of the company’s stock worth $44,000 after purchasing an additional 11,426 shares during the period. 16.66% of the stock is owned by institutional investors and hedge funds.

About Eyenovia

(Get Free Report)

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.

Read More

Earnings History for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.